Smith & Nephew (NYSE:SNN; LSE:SN), the global medical technology business, today announces the launch of its NAVIO handheld robotics-assisted total knee arthroplasty (TKA) application. This expands the NAVIO platform to total knees, which comprise 80% of all knee replacement surgeries globally. The TKA application supports Smith & Nephew’s JOURNEY II, LEGION Primary and GENESIS II Total Knee Systems.
The NAVIO Surgical System is a next generation handheld robotics platform designed to aid surgeons with implant alignment, ligament balancing and bone preparation – key factors that can drive patient satisfaction. The small footprint of the NAVIO Surgical system allows for easy set up and portability. The TKA application provides a streamlined and efficient workflow along with cut guides specifically designed for handheld robotics-assisted surgery. Furthermore, the NAVIO robotics-assisted system does not require a preoperative image, such as a CT scan. This allows patients to receive the benefits of robotics-assistance without the extra steps, costs, and radiation associated with additional preoperative imaging.
“The NAVIO system offers game changing improvements in precision and accuracy without sacrificing efficiency. It allows surgeons the control to create a patient-specific plan in the OR and the confidence to execute with robotic precision”, says Dr Joseph Burkhardt from southwest Michigan. “For the Total Knee, it provides surgeons the ability to do more than they have ever been able to do with standard instruments, resulting in improved functional outcomes for the patient.”
“The NAVIO partial knee replacement application has been commercially available since 2014, including UKA and PFJ options, and has developed a strong surgeon following,” said Glenn Warner, President, US Commercial. “The full market release of the TKA application provides a robotics-assisted solution for one of the largest markets in orthopaedics. Smith & Nephew is committed to continued expansion and growth of the NAVIO robotics-assisted platform.”
Contacts
| Media |
|
| Dave Snyder Smith & Nephew
| +1 (978) 749-1440 |
| Investor/Analyst |
|
| Ingeborg Oie Smith & Nephew | +44 (0)20 7401 7646 |
About Smith & Nephew
Smith & Nephew is a global medical technology business dedicated to helping healthcare professionals improve people's lives. With leadership positions in Orthopaedic Reconstruction, Advanced Wound Management, Sports Medicine and Trauma & Extremities, Smith & Nephew has around 15,000 employees and a presence in more than 100 countries. Annual sales in 2016 were almost $4.7 billion. Smith & Nephew is a member of the FTSE100 (LSE:SN, NYSE:SNN).
For more information about Smith & Nephew, please visit our website www.smith-nephew.com, follow @SmithNephewplc on Twitter or visit SmithNephewplc on Facebook.com.
Forward-looking Statements
This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith & Nephew, these factors include: economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew's most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith & Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith & Nephew are qualified by this caution. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith & Nephew's expectations.
◊ Trademark of Smith & Nephew. Certain marks registered US Patent and Trademark Office.